Number of pages: 100 | Report Format: PDF | Published date: November 03, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
The global cell line development market was pegged at US$ 5.9 billion in 2021 and is expected to witness a CAGR of 10% during the forecast period.
Cell Line Development (CLD) is a technique employed in a wide range of research, drug development, and production applications, including the discovery of therapeutic targets and the synthesis of biologic drugs. The selection of host cells, usually Chinese Hamster Ovary (CHO) or HEK293 cells, is the first step in the procedure. The increasing production of vaccines worldwide, the expansion of the biotechnology industry, and the rise in demand for monoclonal antibodies are all factors contributing to the growth of the cell line development market.
The increasing usage of bio-therapeutics in the treatment of chronic diseases including cancer, diabetes, and arthritis is frequently linked to the expansion of the cell line development industry. This is driving up demand for cell line development services and automated cell line development. The use of cultured cell lines for oncology research, including tumour cells that are more amenable to culturing in-vitro, is a significant driving force for the cell line development industry. Additionally, the manufacture of products now in clinical development makes substantial use of human cell lines under the mammalian cell line development division. Because the human cell lines produce human protein with post-translational changes, they are commonly employed as expression platforms (PTMs).
The global cell line development market has been analysed from five perspectives by product, source, cell line, application and region.
Cell Line Development Market by Product
Based on product, the cell line development market has been segmented into reagent & media, equipment, and accessories & consumables. The equipment segment is sub segmented into centrifuge, incubator, bioreactor, storage equipment, microscope and other. The reagent and media dominated the segment during forecast period. These goods have a high cost of manufacturing and extensive use in the development of biologics; as a result, they accounted for the majority of revenue. Reagents used include attachment and matrix factors, biological buffers, cell freezing, separation and dissociation reagents, and additional unspecified reagents. As they nourish cells and spur growth, media and salt are crucial to the creation of biomaterials. However, due to the growing use of disposables in various procedures, the accessories and consumables segment is predicted to increase profitably. This is due to the expansion of lab facilities for R&D and the production of biologics.
Cell Line Development Market by Source
Based on source, the cell line development market has been segmented into mammalian and non-mammalian. The production of cell lines is started with the collection of organs or tissues from mammals or non-mammalian sources. For the development of stable cell lines for commercial use, source selection is a must. Furthermore, in the upcoming years, it is anticipated that increasing use of a mammalian source for the manufacture of monoclonal antibodies and the requirement to express complex proteins similar to those found in humans would increase the acceptance of this market.
Cell Line Development Market by Cell Line
Based on cell line, the cell line development market has been segmented into recombinant, hybridoma, and continuous cell line and primary cell line. The recombinant segment dominated the market during forecast period due to its extensive use in biologics production processes, gene activation, and protein interactions. In the upcoming years, it is also projected that increased demand would fuel the need for drug screening and toxicity testing.
Cell Line Development Market by Application
Based on application, the cell line development market has been segmented into bioproduction, drug discovery, toxicity testing, tissue engineering, research. The bioproduction segment accounted largest revenue during the forecast period due to increased production of antibiotics and vaccines. The bioproduction application area includes the production of biologics-based therapeutic pharmaceuticals such as vaccines, therapeutic proteins, cell therapies, and gene therapies.
Cell Line Development Market by Region
Based on region, the cell line development market has been segmented into North America, Europe, Asia Pacific, rest of the World. North America dominated the market during forecast period due to novel discoveries and ongoing technological advancements have led to the implementation of novel bioproduction techniques. The development is being attributed to the existence of rigorous initiatives carried out by research organisations operating in this region, such as Thermo Fisher Scientific Inc., American Type Culture Collection (ATCC), and Sigma-Aldrich Corporation, which offer high-quality biologics services. Furthermore, some of the factors anticipated to propel the regional market growth include supportive government initiatives and rising awareness of the use of monoclonal antibodies in the treatment of cancer. Due to rising healthcare spending by the public and private sectors, the Asia Pacific region's market is predicted to grow profitably. During the projection period, it is anticipated that the biotechnology industry in developing nations would experience significant expansion.
Some of the prominent market players in the global cell line development include
The global cell line development market is expected to clock US$ 14.15 billion by 2030.
The global cell line development market is expected to witness a CAGR of 10% during the forecast period.
Some of the prominent market players in the global cell line development include GE Healthcare, Advanced Instruments, LLC., Lonza Group AG and others.
Increasing acceptance of mammalian sources for antibody production.
The difficulty of establishing reliable and authentic cell lines is prime restraining factor.
*Insights on financial performance is subject to availability of information in public domain